Bioequivalence in the real world is a complex challenge: the case of clopidogrel. - Suppr | 超能文献

Bioequivalence in the real world is a complex challenge: the case of clopidogrel.

作者信息

Marcucci Rossella, Paniccia Rita, Gori Anna Maria, Gensini Gian Franco, Abbate Rosanna

出版信息

J Am Coll Cardiol. 2013 Feb 5;61(5):594-5. doi: 10.1016/j.jacc.2012.10.020. Epub 2012 Dec 12.

DOI:10.1016/j.jacc.2012.10.020

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Bioequivalence in the real world is a complex challenge: the case of clopidogrel.

J Am Coll Cardiol. 2013 Feb 5;61(5):594-5. doi: 10.1016/j.jacc.2012.10.020. Epub 2012 Dec 12.

2

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.

Circulation. 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18.

3

Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.

Aliment Pharmacol Ther. 2011 Jan;33(1):77-88. doi: 10.1111/j.1365-2036.2010.04485.x. Epub 2010 Oct 19.

4

Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.

Clin Ther. 2006 Jun;28(6):860-71. doi: 10.1016/j.clinthera.2006.06.010.

5

Clopidogrel: new indication. In combination with aspirin: marginal additional benefits.

Prescrire Int. 2007 Aug;16(90):146.

6

Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice.

Int J Cardiol. 2013 Sep 20;168(1):589-90. doi: 10.1016/j.ijcard.2013.01.246. Epub 2013 Feb 26.

7

[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].

MMW Fortschr Med. 2004;146 Suppl 1:9-10.

8

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).

Am J Cardiol. 2006 Nov 1;98(9):1125-31. doi: 10.1016/j.amjcard.2006.05.043. Epub 2006 Aug 31.

9

[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].

MMW Fortschr Med. 2004;146 Suppl 1:4-5.

10

Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.

Am J Cardiol. 2010 Sep 1;106(5):619-23. doi: 10.1016/j.amjcard.2010.04.015.

引用本文的文献

1

The incidence of recurrent cardiovascular events among acute coronary syndrome patients treated with generic or original clopidogrel in relation to their sociodemographic and clinical characteristics. The Aegean study.

Arch Med Sci. 2020 May 30;16(5):1013-1021. doi: 10.5114/aoms.2020.95878. eCollection 2020.

2

Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.

J Thromb Thrombolysis. 2017 Nov;44(4):466-474. doi: 10.1007/s11239-017-1567-0.